ArticleEuropean journal of pediatrics2026
Evaluation of FABP1 as a biomarker of diabetic kidney disease in children with type 1 diabetes.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is a chronic microvascular complication of diabetes mellitus and a leading cause of chronic kidney disease worldwide. Microalbuminuria remains the current gold standard for the diagnosis and staging of DKD; however, it often reflects established renal injury rather than early pathological changes. Fatty acid-binding protein 1 (FABP1), a cytoplasmic protein abundantly expressed in the renal proximal tubules, is released into the urine in response to tubular damage. FABP1 plays an essential role in intracellular fatty acid transport and metabolism and may serve as a potential biomarker for tubular involvement in pediatric diabetic kidney disease. A case-control study was performed on 90 children (30 T1DM with DKD, 30 T1DM without DKD [non-DKD], and 30 controls). Albumin-creatinine ratio (ACR) and serum FABP1 were ELISA measured. FABP1 was significantly higher in the DKD group versus non-DKD (p = 0.026) and controls (p = 0.009). FABP1 positively correlated with ACR (r = 0.25, p = 0.018), total cholesterol (r = 0.25, p = 0.019), and LDL-C (r = 0.25, p = 0.017). A cutoff > 189 ng/L discriminated DKD from non-DKD (AUC = 0.67, sensitivity 63%, specificity 73%).Conclusion: Serum FABP1 may represent a complementary biomarker of tubular involvement in pediatric diabetic kidney disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.